Adjunctive homeopathic treatment of hospitalized COVID-19 patients (COVIHOM): A retrospective case series.
COVID-19
Complementary therapies
Homeopathy
Intensive care unit
SARS-CoV-2
Journal
Complementary therapies in clinical practice
ISSN: 1873-6947
Titre abrégé: Complement Ther Clin Pract
Pays: England
ID NLM: 101225531
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
18
10
2020
revised:
04
05
2021
accepted:
05
05
2021
pubmed:
15
5
2021
medline:
4
8
2021
entrez:
14
5
2021
Statut:
ppublish
Résumé
and purpose. COVID-19 is a novel viral disease causing worldwide pandemia. The aim of this study was to describe the effect of adjunctive individualized homeopathic treatment delivered to hospitalized patients with confirmed symptomatic SARS-CoV-2 infection. Thirteen patients with COVID-19 were admitted. Mean age was 73.4 ± 15.0 (SD) years. Twelve (92.3%) were speedily discharged without relevant sequelae after 14.4 ± 8.9 days. A single patient admitted in an advanced stage of septic disease died in hospital. A time-dependent improvement of relevant clinical symptoms was observed in the 12 surviving patients. Six (46.2%) were critically ill and treated in the intensive care unit (ICU). Mean stay at the ICU of the 5 surviving patients was 18.8 ± 6.8 days. In six patients (46.2%) gastrointestinal disorders accompanied COVID-19. The observations suggest that adjunctive homeopathic treatment may be helpful to treat patients with confirmed COVID-19 even in high - risk patients especially since there is no conventional treatment of COVID-19 available at present.
Sections du résumé
BACKGROUND
BACKGROUND
and purpose. COVID-19 is a novel viral disease causing worldwide pandemia. The aim of this study was to describe the effect of adjunctive individualized homeopathic treatment delivered to hospitalized patients with confirmed symptomatic SARS-CoV-2 infection.
PATIENT PRESENTATION
METHODS
Thirteen patients with COVID-19 were admitted. Mean age was 73.4 ± 15.0 (SD) years. Twelve (92.3%) were speedily discharged without relevant sequelae after 14.4 ± 8.9 days. A single patient admitted in an advanced stage of septic disease died in hospital. A time-dependent improvement of relevant clinical symptoms was observed in the 12 surviving patients. Six (46.2%) were critically ill and treated in the intensive care unit (ICU). Mean stay at the ICU of the 5 surviving patients was 18.8 ± 6.8 days. In six patients (46.2%) gastrointestinal disorders accompanied COVID-19.
CONCLUSION
CONCLUSIONS
The observations suggest that adjunctive homeopathic treatment may be helpful to treat patients with confirmed COVID-19 even in high - risk patients especially since there is no conventional treatment of COVID-19 available at present.
Identifiants
pubmed: 33989861
pii: S1744-3881(21)00114-6
doi: 10.1016/j.ctcp.2021.101415
pmc: PMC8110319
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101415Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Respir Med. 2019 Jan;146:96-105
pubmed: 30665525
Homeopathy. 2020 Nov;109(4):191-197
pubmed: 32215892
Homeopathy. 2005 Apr;94(2):75-80
pubmed: 15892486
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Homeopathy. 2020 Aug;109(3):167-168
pubmed: 32643783
Rev Assoc Med Bras (1992). 2020 Apr;66(4):405-406
pubmed: 32578770
Sci Total Environ. 2020 Aug 1;728:138861
pubmed: 32344226
Homeopathy. 2020 Aug;109(3):182-183
pubmed: 32516818
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5819-5829
pubmed: 32495921
Syst Rev. 2014 Dec 06;3:142
pubmed: 25480654
Homeopathy. 2020 Aug;109(3):146-162
pubmed: 32503061
Homeopathy. 2018 Aug;107(3):157-160
pubmed: 29753299
Homeopathy. 2020 Aug;109(3):169-175
pubmed: 32698230
Homeopathy. 2020 Aug;109(3):176-178
pubmed: 32503062
Schweiz Arch Tierheilkd. 2020 Oct;162(10):597-615
pubmed: 33006555
Homeopathy. 2021 May;110(2):86-93
pubmed: 33567460